Novo Nordisk to boost obesity drugs manufacturing capacity
Frankfurt: Novo Nordisk said it will boost manufacturing capacity for future obesity drug launches and worry less about marketing and advertising after a bungled market introduction of its Wegovy injection last year."As we look to launch future products, obviously we will take into consideration more of a 'pull' than a 'push' commercial strategy. And that links into how we scale capacity...
Login or Register to read the full article
Frankfurt: Novo Nordisk said it will boost manufacturing capacity for future obesity drug launches and worry less about marketing and advertising after a bungled market introduction of its Wegovy injection last year.
"As we look to launch future products, obviously we will take into consideration more of a 'pull' than a 'push' commercial strategy. And that links into how we scale capacity for that," Chief Executive Lars Fruergaard Jorgensen told journalists in a call on nine-month results.
"We see this pull nature in the market for anti-obesity medicine, which is fantastic because we have the broadest portfolio in the industry to do that," he added.
The company is in a drawn-out production revamp after a contractor filling Wegovy injection pens ran into problems late last year.
Read also: Novo Nordisk Eptacog alfa gets CDSCO panel nod for Additional Indication
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd